Additional information
| Therapeutic Segment | Immunosuppressants |
|---|---|
| Dosage Form | Tablets |
| Specialities | Gastroenterologist, Nephrologist, Urologist |
Sirolimus, also known as rapamycin, works by binding to the FK506-binding protein-12 (FKBP-12) receptor in cells to form a complex that inhibits the mammalian target of rapamycin (mTOR). This inhibition has several effects, including -
Suppressing T-cell proliferation: Sirolimus prevents the progression of T-cells from the G1 to the S phase of the cell cycle.
Inhibiting antibody production: Sirolimus prevents the production of antibodies.
Reducing DNA transcription, translation, and protein synthesis: Sirolimus reduces these processes in activated lymphocytes.
As directed by physician
